In This Article:
In the last week, the Indian market has stayed flat, yet it is up 44% over the past year with earnings expected to grow by 17% per annum over the next few years. In such a dynamic environment, identifying stocks with strong growth potential and solid fundamentals can be key to enhancing your portfolio.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Shree Digvijay Cement | 0.01% | 13.97% | 16.37% | ★★★★★★ |
| Vidhi Specialty Food Ingredients | 7.27% | 11.00% | 4.02% | ★★★★★★ |
| Aeroflex Industries | 0.04% | 14.69% | 33.38% | ★★★★★★ |
| Knowledge Marine & Engineering Works | 35.48% | 46.55% | 46.96% | ★★★★★★ |
| Bengal & Assam | 4.48% | 1.54% | 51.11% | ★★★★★☆ |
| Voith Paper Fabrics India | 0.07% | 10.95% | 9.70% | ★★★★★☆ |
| Gallantt Ispat | 18.85% | 37.56% | 37.26% | ★★★★★☆ |
| Piccadily Agro Industries | 50.57% | 13.86% | 42.85% | ★★★★★☆ |
| Insolation Energy | 88.64% | 163.87% | 419.31% | ★★★★★☆ |
| Sanstar | 50.30% | -8.41% | 48.59% | ★★★★☆☆ |
We're going to check out a few of the best picks from our screener tool.
IIFL Securities
Simply Wall St Value Rating: ★★★★☆☆
Overview: IIFL Securities Limited offers capital market services in India's primary and secondary markets, with a market cap of ₹68.43 billion.
Operations: IIFL Securities Limited generates revenue primarily from capital market activities (₹20.25 billion), with additional income from facilities and ancillary services (₹375.25 million) and insurance broking and ancillary services (₹2.77 billion).
IIFL Securities, a notable player in India's financial sector, has shown impressive earnings growth of 120.4% over the past year, outpacing the industry average of 64%. The company's price-to-earnings ratio stands at an attractive 12.4x compared to the Indian market's 32.9x. Despite recent volatility in share price and a penalty from SEBI for technical errors, IIFLSEC's net debt to equity ratio is satisfactory at 35.5%, and its high-quality earnings underscore its potential as an investment gem.
-
Get an in-depth perspective on IIFL Securities' performance by reading our health report here.
-
Evaluate IIFL Securities' historical performance by accessing our past performance report.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally and has a market cap of ₹99.76 billion.
Operations: Marksans Pharma Limited generates revenue primarily from its pharmaceutical segment, which amounted to ₹22.68 billion. The company has a market cap of ₹99.76 billion.